Abstract:Proteolysis-targeting chimeras (PROTACs) are hetero-bifunctional molecules. They induce the degradation of a target protein by recruiting an E3 ligase to the target. The PROTAC can inactivate disease-related genes that are considered as understudied, thus has a great potential to be a new type of therapy for the treatment of incurable diseases. However, only hundreds of proteins have been experimentally tested if they are amenable to the PROTACs. It remains elusive what other proteins can be targeted by the PROTAC in the entire human genome. For the first time, we have developed an interpretable machine learning model PrePROTAC, which is based on a transformer-based protein sequence descriptor and random forest classification to predict genome-wide PROTAC-induced targets degradable by CRBN, one of the E3 ligases. In the benchmark studies, PrePROTAC achieved ROC-AUC of 0.81, PR-AUC of 0.84, and over 40% sensitivity at a false positive rate of 0.05, respectively. Furthermore, we developed an embedding SHapley Additive exPlanations (eSHAP) method to identify positions in the protein structure, which play key roles in the PROTAC activity. The key residues identified were consistent with our existing knowledge. We applied PrePROTAC to identify more than 600 novel understudied proteins that are potentially degradable by CRBN, and proposed PROTAC compounds for three novel drug targets associated with Alzheimer's disease. Author summary: Many human diseases remain incurable because disease-causing genes cannot by selectively and effectively targeted by small molecules. Proteolysis-targeting chimera (PROTAC), an organic compound that binds to both a target and a degradation-mediating E3 ligase, has emerged as a promising approach to selectively target disease-driving genes that are not druggable by small molecules. Nevertheless, not all of proteins can be accommodated by E3 ligases, and be effectively degraded. Knowledge on the degradability of a protein will be crucial for the design of PROTACs. However, only hundreds of proteins have been experimentally tested if they are amenable to the PROTACs. It remains elusive what other proteins can be targeted by the PROTAC in the entire human genome. In this paper, we propose an intepretable machine learning model PrePROTAC that takes advantage of powerful protein language modeling. PrePROTAC achieves high accuracy when evaluated by an external dataset which comes from different gene families from the proteins in the training data, suggesting the generalizability of PrePROTAC. We apply PrePROTAC to the human genome, and identify more than 600 understudied proteins that are potentially responsive to the PROTAC. Furthermore, we design three PROTAC compounds for novel drug targets associated with Alzheimer's disease.

A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy

A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach

De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy

Development of PROTACs Using Computational Approaches

Hotspot-Driven Peptide Design via Multi-Fragment Autoregressive Extension

AI-DPAPT: a machine learning framework for predicting PROTAC activity

Peptide-based drug discovery through artificial intelligence: towards an autonomous design of therapeutic peptides

Abstract LB151: Deep learning - based protein therapeutics design to treat HER2+ cancers

An overview of PROTACs: a promising drug discovery paradigm

Elucidation of Genome-wide Understudied Proteins targeted by PROTAC-induced degradation using Interpretable Machine Learning

De novo PROTAC design using graph-based deep generative models

Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs)

De novo design of high-affinity protein binders with AlphaProteo

Artificial Intelligence in De novo Drug Design: Are We Still There?

AI-powered therapeutic target discovery

AI for targeted polypharmacology: The next frontier in drug discovery

AI-Bind: Improving Binding Predictions for Novel Protein Targets and Ligands

Improving the generalizability of protein-ligand binding predictions with AI-Bind

The role and future prospects of artificial intelligence algorithms in peptide drug development

PROTAC technology: From drug development to probe technology for target deconvolution

Discovery of Multitarget-Directed Ligands Against Alzheimer'S Disease Through Systematic Prediction of Chemical Protein Interactions